Effect of Tocilizumab in Hospitalized Patients with Severe COVID-19 Pneumonia: A Case-Control Cohort Study
Tocilizumab, an anti-interleukin-6 receptor, administrated during the right timeframe may be beneficial against coronavirus-disease-2019 (COVID-19) pneumonia. All patients admitted for severe COVID-19 pneumonia (SpO2 ≤ 96% despite O2-support ≥ 6 L/min) without invasive mechanical ventilation were in...
Main Authors: | Benjamin Rossi, Lee S. Nguyen, Philippe Zimmermann, Faiza Boucenna, Louis Dubret, Louise Baucher, Helene Guillot, Marie-Anne Bouldouyre, Yves Allenbach, Joe-Elie Salem, Paul Barsoum, Arezki Oufella, Helene Gros |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-10-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/13/10/317 |
Similar Items
-
Tocilizumab: A potent immunomodulatory agent in the treatment of COVID-19 pneumonia
by: Sameer Bansal, et al.
Published: (2021-01-01) -
Tocilizumab for treatment of patients with severe COVID–19: A retrospective cohort study
by: Tariq Kewan, et al.
Published: (2020-07-01) -
Tocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Release Syndrome
by: Tom van Kraaij, et al.
Published: (2020-04-01) -
Tocilizumab: The Key to Stop Coronavirus Disease 2019 (COVID-19)-Induced Cytokine Release Syndrome (CRS)?
by: Danfei Liu, et al.
Published: (2020-10-01) -
PROSPECTS FOR USING TOCILIZUMAB IN SYSTEMIC SCLEROSIS
by: L. P. Ananyeva
Published: (2016-02-01)